Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Por Duvic, Madeleine, Talpur, Rakshandra, Ni, Xiao, Zhang, Chunlei, Hazarika, Parul, Kelly, Cecilia, Chiao, Judy H., Reilly, John F., Ricker, Justin L., Richon, Victoria M., Frankel, Stanley R.
Publicado em 2007

Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome

Por Kantarjian, Hagop, Garcia-Manero, Guillermo, O'Brien, Susan, Faderl, Stefan, Ravandi, Farhad, Westwood, Robert, Green, Simon R., Chiao, Judy H., Boone, Patricia A., Cortes, Jorge, Plunkett, William
Publicado em 2010

Results of a Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Previously Untreated or First Relapsed Acute Myeloid Leukemia

Por Kantarjian, Hagop, Faderl, Stefan, Garcia-Manero, Guillermo, Luger, Selina, Venugopal, Parameswaran, Maness, Lori, Wetzler, Meir, Coutre, Steven, Stock, Wendy, Claxton, David, Goldberg, Stuart L., Arellano, Martha, Strickland, Stephen A., Seiter, Karen, Schiller, Gary, Jabbour, Elias, Chiao, Judy, Plunkett, William
Publicado em 2012

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

Por Kelly, William Kevin, O’Connor, Owen A., Lee Krug, M., Chiao, Judy H., Heaney, Mark, Curley, Tracy, MacGregore-Cortelli, Barbara, Tong, William, Secrist, J. Paul, Schwartz, Lawrence, Richardson, Stacy, Chu, Elaina, Olgac, Semra, Marks, Paul A., Scher, Howard, Richon, Victoria M.
Publicado em 2005